Last €8.14 EUR
Change Today -0.224 / -2.68%
Volume 0.0
B9M On Other Exchanges
Symbol
Exchange
London
Berlin
OTC US
As of 9:43 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

btg plc (B9M) Snapshot

Open
€8.14
Previous Close
€8.37
Day High
€8.30
Day Low
€8.14
52 Week High
08/27/14 - €8.37
52 Week Low
10/11/13 - €4.08
Market Cap
3.0B
Average Volume 10 Days
21.6
EPS TTM
--
Shares Outstanding
362.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BTG PLC (B9M)

Related News

No related news articles were found.

btg plc (B9M) Related Businessweek News

No Related Businessweek News Found

btg plc (B9M) Details

BTG plc, a specialist healthcare company, develops and commercializes products targeting critical care, cancer, and varicose veins. It operates through three segments: Specialty Pharmaceuticals, Interventional Medicine, and Licensing & Biotechnology. The company markets and sells specialty pharmaceuticals, including CroFab, a treatment for patients bitten by North American pit vipers; DigiFab, a treatment for patients suffering toxicity associated with the use of the heart medicine digoxin; and Voraxaze, a treatment for toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function. It also offers a range of interventional oncology products comprising Bead Block, TheraSphere, LC Bead, and DC Bead used to treat patients with hypervascularized tumors; and EkoSonic Endovascular System for the treatment of patients with severe blood clots, and Varithena polidocanol injectable foam for the treatment for patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. The company’s products in late-stage development include TheraSphere in Phase 3 clinical trials in hepatocellular carcinoma (HCC) and 2nd line metastatic colorectal cancer (mCRC); Beads in investigator-initiated/registration studies in HCC and 3rd line mCRC; and Uridine triacetate in development with Wellstat Therapeutic Corporation as a treatment for toxicity associated with the use of the chemotherapeutic 5-fluorouracil. The company’s licensing products comprise Zytiga, a treatment for patients with prostate cancer; Two-Part Hip Cup, a prosthetic hip joint replacement licensed to hip-replacement technology manufacturers; and Lemtrada, a treatment for patients with relapsing-remitting multiple sclerosis. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

860 Employees
Last Reported Date: 06/16/14
Founded in 1948

btg plc (B9M) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 1.0M GBP
Chief Financial Officer, Executive Director a...
Total Annual Compensation: 657.0K GBP
Compensation as of Fiscal Year 2014.

btg plc (B9M) Key Developments

China Food and Drug Administration Approves Registration of DC Bead for the Embolisation of Malignant Hypervascularised Tumours

BTG plc and SciClone Pharmaceuticals, Inc. announced that the China Food and Drug Administration has approved the registration of DC Bead for the embolisation of malignant hypervascularised tumours. BTG and SciClone previously entered into an agreement granting SciClone exclusive licensing and distribution rights to DC Bead® in China. Under the agreement, SciClone will purchase product from BTG at a specified price for sale in China. Commercial launch plans are now underway. DC Bead® is a novel treatment for liver cancer which is currently approved in 40 countries worldwide, including Europe. DC Bead® is an embolic bead delivered through a minimally invasive, non-surgical procedure to block the blood flow to tumours.

BTG plc Provides Revenue Guidance for the Year 2014

BTG plc provided revenue guidance for the year 2014. For the year, the company announced trading during the period has been in line with the Board's expectations across all business segments. Full year revenue is expected to be in the £330 million to £345 million range as previously guided, despite the recent weakening of the USD versus sterling.

BTG plc to Report 4 Months 2014 Interim Management Statement on Jul 16, 2014

BTG plc announced that they will report 4 months, 2014 interim management statement on Jul 16, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
B9M:GR €8.14 EUR -0.224

B9M Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Richter Gedeon Nyrt 3,851 -43.00
Merit Medical Systems Inc $12.33 USD -0.11
Pfizer Ltd/India 1,423 INR -14.95
RPX Corp $15.10 USD +0.05
Wi-Lan Inc C$4.11 CAD -0.10
View Industry Companies
 

Industry Analysis

B9M

Industry Average

Valuation B9M Industry Range
Price/Earnings 97.4x
Price/Sales 8.2x
Price/Book 4.5x
Price/Cash Flow 50.1x
TEV/Sales 8.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BTG PLC, please visit www.btgplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.